Form: 3

Initial statement of beneficial ownership of securities

November 25, 2025

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Durocher John
(Last) (First) (Middle)
C/O CALIX, INC.
3155 OLSEN DRIVE, SUITE 450
(Street)
SAN JOSE CA 95117
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/16/2025 		3. Issuer Name and Ticker or Trading Symbol
CALIX, INC [ (CALX) ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
COO
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 1,928 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) 03/24/2033 Common Stock 200,000 51.83 D
Stock Option (right to buy) (2) 03/24/2033 Common Stock 42,555 51.83 D
Stock Option (right to buy) (3) 02/08/2034 Common Stock 107,775 34.26 D
Stock Option (right to buy) (4) 02/08/2034 Common Stock 56,350 34.26 D
Stock Option (right to buy) (5) 01/31/2035 Common Stock 195,000 39.68 D
Stock Option (right to buy) (6) 01/31/2035 Common Stock 195,000 39.68 D
Explanation of Responses:
1. 25% of the shares subject to the stock option grant vested on March 24, 2024, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 125,000 shares subject to the option grant are fully vested and exercisable.
2. 25% of the shares subject to the stock option grant vested on March 24, 2024, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 26,597 shares subject to the option grant are fully vested and exercisable.
3. 25% of the shares subject to the stock option grant vested on February 8, 2025, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 47,151 shares subject to the option grant are fully vested and exercisable.
4. 25% of the shares subject to the stock option grant vested on February 8, 2025, with the remainder vesting quarterly thereafter in substantially equal installments over the next 36 months, subject to the reporting person's service through each applicable vesting date. As of November 25, 2025, 17,622 shares subject to the option grant are fully vested and exercisable.
5. 25% of these stock options will vest on the first anniversary of the grant date. Thereafter, the remainder of these stock options will vest quarterly in substantially equal installments over the next 36 months, subject to Reporting Person's continued service through each vesting date.
6. The nonqualified stock option award shall vest: (i) as to 25% of the shares of common stock subject to the stock option award, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the stock option award, quarterly in equal installments over 36 months from January 31, 2026, subject to the reporting person's continued employment with Calix through the applicable vesting dates.
Remarks:
/s/ Tom Gemetti as Attorney-in-Fact for John Durocher 11/25/2025
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.